AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DAWN
  4. [SCHEDULE 13G] Day One Biopharmaceuticals, Inc. SEC Filing

[SCHEDULE 13G] Day One Biopharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock DAWN logo
Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

#4051 Ranked by Market Cap
N/A Ranked by Dividends

DAWN Latest News

Aug 5, 2025
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
Jul 22, 2025
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
Jun 10, 2025
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
May 6, 2025
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
Apr 22, 2025
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

DAWN Latest SEC Filings

Aug 6, 2025
[SCHEDULE 13G/A] Day One Biopharmaceuticals, Inc. SEC Filing
Aug 5, 2025
[10-Q] Day One Biopharmaceuticals, Inc. Quarterly Earnings Report
Aug 5, 2025
[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event
Jul 14, 2025
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity
Jun 18, 2025
[Form 3] Day One Biopharmaceuticals, Inc. Initial Statement of Beneficial Ownership

DAWN Stock Data

697.37M
84.03M
17.05%
94.82%
10.14%
Biotechnology
Pharmaceutical Preparations
United States
BRISBANE